News

Increasing e-cigarette sales and flavor shifts underscore the need for stricter regulations, according to a CDC Foundation, Truth Initiative.

The analysis, from ADA 2023, additionally indicated SGLT2 inhibition showed no effect on the risk of requiring intravitreal injection treatment for DME.

A new study highlights the benefits of using the hypertonic saline test to determine the appropriate dose of inhaled corticosteroids for managing asthma in children.

Data from a phase 2 substudy of retatrutide indicates use could reduce liver fat content and contribute to resolution of NAFLD in people with NAFLD and obesity.

In this Q&A interview with physician assistant Renata Block, Block spoke on some of her thoughts about the recent SDPA conference and its presentations.

W. Timothy Garvey, MD, sits down to discuss the results of SURMOUNT-2, the ongoing revolution of antiobesity medications, and why he is concerned over the growing prevalence of online weight loss clinics

The American Academy of Sleep Medicine revised the guidelines for REM sleep behavior disorder for the first time since 2010.

This interview featured a discussion with Dr. Mostaghimi, during which he described some of the latest treatments for alopecia, new policies and efforts for patients, and general conference takeaways.

BOS-580 is an investigational, proprietary, long-acting fibroblast growth factor 21 analog as a monthly and bi-weekly treatment for patients with NASH.

Significant improvements seen in hematologic parameters, visceral volumes, and plasma biomarkers in patients with Gaucher disease, suggesting its potential as an alternative therapy, particularly for those who cannot access enzyme replacement therapy.

Of the randomized controlled trials identified, only 41% involved patients with depression.

Use of metformin was associated with significant reductions in the risk of developing POAG beyond glycemic control, according to an analysis presented at ADA 2023.

Significant cases of missed diagnoses of iron-deficiency emphasize the need for improved screening strategies and proactive measures to address these health risks.

The letter makes reference to an ongoing review of inspection findings from a third-party filler involved with the drug development. Regeneron will not require additional trial data.

APX3330 showed statistically significant prevention of ≥3-step binocular DRSS worsening compared to placebo, but did not meet the study's primary endpoint.

Obstructive sleep apnea was linked to an increased risk of gout in the female subgroup.

Telehealth likely will have a major place in psychiatric care in the future.

In this interview, physician assistant Hope Cook described some of the major talking points from her conference talk titled ‘Healing PA Burnout.’

For participants reporting past-year suicidal experiences, there was decreased odds of attributing their suicidal experiences to the pandemic for veterans compared to nonveterans.

In this discussion with HCPLive, Dr. Markowitz spoke about some of the biggest takeaways from her conference presentation on skin cancer treatments.

Data from a pair of phase 2 trials in patients with overweight/obesity and type 2 diabetes presented at ADA 2023 suggest the GIP/GLP-1/Glucagon agonist retatrutide could provide significant weight loss and glycemic control benefits.

Optum Rx announced it will place the biosimilar adalimumab-adbm (Cyltezo) injection on its commercial formulary as a preferred brand.

A 7-year longitudinal analysis presented at ADA 2023 suggests time in range was associated with an increased risk of diabetic retinopathy in people with type 1 diabetes.

Hosts are joined by Cari Berget, RN, MPH, for a deep dive into her efforts to improve the implementation of the latest diabetes technologies in real-world settings through her role as a director of the PANTHER Program.

An analysis presented at ADA 2023 suggests autonomous artificial intelligence testing for diabetic eye diseases promoted health equity across various patient subgroups.

Data from a pair of trials presented at ADA 2023 suggests an upped dose of oral semaglutide could soon be on the horizon, with results supporting use in chronic weight management as well as type 2 diabetes.

Most patients with lupus nephritis reported moderate anxiety and moderate depression which impacted their disease activity and quality of life.

Results from the EMPRISE study presented at ADA 2023 showed empagliflozin was associated with a 23% reduction in the risk of diabetic retinopathy progression in adults with T2D.

Ritlecitinib becomes the second JAK inhibitor approved to treat alopecia—and the first to be indicated for patients aged 12 years and older.

Communities already facing social vulnerabilities are more likely to bear the burden of increased smoke exposure.